Spots Global Cancer Trial Database for ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016
Official Title: Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment naïve Acute Lymphoblastic Leukemia
Study ID: NCT03286634
Study Description
Brief Summary: To evaluate the outcome of a prednisolone and low dose methotrexate based protocol in Down syndrome children with ALL (DS-ALL) in an Asia-wide study. The treatment protocol was modified based upon backbone of Taiwan Pediatric Oncology Group (TPOG)-ALL protocol in which risk classification will be guided by level of flow minimal residual disease (MRD) instead.
Detailed Description:
Keywords
Eligibility
Minimum Age: 0 Years
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Prince of Wales Hospital, Shatin, New Territories, Hong Kong
Kagoshima University Hospital, Kagoshima, , Japan
University of Malaya Medical Centre, Kuala Lumpur, , Malaysia
Subang Jaya Medical Centre, Subang Jaya, , Malaysia
National University Hospital, Singapore, , Singapore
KK Women's and Children's Hospital, Singapore, , Singapore
National Taiwan University Children's Hospital, Taipei, , Taiwan
Mackay Memorial Hospital, Taipei, , Taiwan
Chang Gung Memorial Hopsital, Linkou, Taoyuan, , Taiwan
Siriraj Hospital Mahidol University, Bangkok, , Thailand
Contact Details
Name: Allen Yeoh, MBBS
Affiliation: National University Hospital, Singapore
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
